AtaiBeckley Inc. (ATAI)

Profile

https://www.ataibeckley.com

AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders. The company concentrates on psychedelic-based and other novel neuroactive compounds designed to offer rapid-acting, durable, and convenient therapeutic options for people with difficult-to-treat psychiatric conditions, such as treatment-resistant depression, social anxiety disorder, and opioid use disorder. AtaiBeckley operates primarily within the healthcare sector, spanning biotechnology, pharmaceutical research and development, and interventional psychiatry, with research and development activities as its main operational focus. Its pipeline includes investigational therapies like BPL-003, an intranasal 5-MeO-DMT formulation, VLS-01, a DMT buccal film, and EMP-01, an oral R-MDMA candidate, all targeting high-unmet-need mental health indications. Headquartered in New York, United States, and founded in 2025 following the combination of atai Life Sciences and Beckley Psytech, AtaiBeckley today serves as a specialized player in the emerging field of psychedelic-inspired psychiatric therapeutics, aiming to address gaps left by conventional treatments.